2024 World Conference on Lung Cancer (WCLC) - Posters-P2.07A.02 The Effect of EGFR Mutation on Adjuvant Tegafur/Uracil for Patients with Non-Lymph Node Metastatic NSCLC (> 2 Cm)

P2.07A.02 The Effect of EGFR Mutation on Adjuvant Tegafur/Uracil for Patients with Non-Lymph Node Metastatic NSCLC (> 2 Cm)

Back to course

Pdf Summary

The study examines the effect of EGFR mutations on the adjuvant chemotherapy efficacy of Tegafur/Uracil (UFT) for patients with non-lymph node metastatic non-small cell lung cancer (NSCLC) measuring 2 cm. This research stems from the context of the ADAURA trial, which established osimertinib's significant efficacy in enhancing disease-free survival (DFS) and overall survival (OS) in patients with certain stages of EGFR mutant NSCLC. However, Japanese patients with tumors measuring 3 cm, traditionally treated with oral UFT, were not included in the ADAURA trial. Consequently, the study investigates UFT's therapeutic efficacy for lung cancer with EGFR mutations.<br /><br />Conducted through the CSPOR-LC03 observational study, the research involved analyzing data from 2008 to 2013 across multiple centers in Japan. The study focused on 1,812 patients meeting specific criteria such as pathological stage I and no prior treatments. Among them, 933 had EGFR mutations, with 394 receiving UFT adjuvant therapy. The primary endpoint was the 5-year DFS rate. <br /><br />The results revealed that the benefit of adjuvant UFT on DFS and OS was limited irrespective of EGFR mutation status. Analysis indicated that patients receiving UFT had a worse prognosis compared to those not receiving it, attributed to a selection bias where UFT was given to those at higher risk of recurrence. The study concluded that in lung adenocarcinomas with EGFR mutation at pathologic stage I (2 cm), adjuvant UFT did not provide a survival benefit. This highlights the need for alternative treatments like osimertinib in the treatment regimen for these specific patient groups.

Asset Subtitle

Tomohiro Miyoshi

Meta Tag

Speaker Tomohiro Miyoshi

Topic Early-Stage NSCLC

Keywords

EGFR mutations

adjuvant chemotherapy

Tegafur/Uracil

non-small cell lung cancer

ADAURA trial

osimertinib

disease-free survival

Japanese patients

CSPOR-LC03 study

lung adenocarcinomas